# Eli Lilly agrees to buy privately held cancer biotech Kelonia Therapeutics for up to $7 billion in cash.

*biotech · news · 2026-04-20 · MarketScreener*

## Key points

- Eli Lilly will acquire Kelonia Therapeutics for up to $7 billion in cash.
- The deal includes an upfront payment of $3.25 billion to Kelonia's owners.
- Kelonia Therapeutics is developing a next-generation therapy for multiple myeloma.
- Pharma deals between $1 billion and $10 billion made up most transactions this year's first quarter.
- Eli Lilly also recently acquired Centessa Pharmaceuticals, Orna Therapeutics, and Ventyx Biosciences.

**Companies:** Eli Lilly, Kelonia Therapeutics
**Countries:** United States

[Read the full story on MarketScreener](https://www.marketscreener.com/news/eli-lilly-to-buy-kelonia-therapeutics-for-initial-3-25-billion-ce7f59dad88af721)

---

Canonical: https://newsio.io/n/77a028d3-cbfc-48fa-b402-65979b4559cc/eli-lilly-agrees-to-buy-privately-held-cancer-biotech-kelonia-therapeutics-for-u
Summarized by Newsio from MarketScreener. https://newsio.io/how-it-works